Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Bancroft, EA (October 2007). "Antimicrobial resistance: it's not just for hospitals". JAMA. 298 (15): 1803–1804. doi:10.1001/jama.298.15.1803. PMC 2536104. PMID 17940239. Larson, E (2007). "Community factors in the development of antibiotic resistance". Annual Review of Public Health. 28 (1): 435–447. doi:10.1146/annurev.publhealth.28.021406.144020. PMID 17094768.
=== Colony forming unit – Hill === As originally isolated by Asahara et al., the CFU-Hill population is an early outgrowth, formed by plating peripheral blood mononuclear cells on fibronectin-coated dishes, allowing adhesion and depleting non-adherent cells, and isolating discrete colonies.
AMP + diphosphate + GMP + L-glutamate The 4 substrates of this enzyme are ATP, xanthosine 5'-phosphate, L-glutamine, and H2O, whereas its 4 products are AMP, diphosphate, GMP, and L-glutamate. This enzyme belongs to the family of ligases, specifically those forming carbon-nitrogen bonds carbon-nitrogen ligases with glutamine as amido-N-donor. The systematic name of this enzyme class is xanthosine-5'-phosphate:L-glutamine amido-ligase (AMP-forming). This enzyme participates in purine metabolism and glutamate metabolism. At least one compound, Psicofuranin is known to inhibit this enzyme.
The Administrative and Program Enrichment Core coordinates Center activities, provides biostatistical support, promotes community engagement, and facilitates career development through seminars, workshops, and the internationally recognized Masoro-Barshop Conference on Aging. The Aging Animal and Functional Assessment Core offers access to aged animal colonies, longevity studies, and comprehensive assessments of physical and physiological function. The GeroMetabolism Core provides advanced metabolomic, lipidomic, and metabolic phenotyping capabilities that enable investigators to examine metabolic mechanisms underlying aging and age-related diseases. The Pathology Core delivers expert histopathologic evaluation and disease phenotyping across multiple organ systems, while the Pharmacology and Drug Design Core supports the identification, optimization, and evaluation of pharmacological interventions targeting aging pathways. Finally, the Research Development Core expands aging research by providing pilot funding, mentorship, trainee support, and access to Center resources for investigators both within UT Health San Antonio and across the United States. A distinguishing strength of the San Antonio Nathan Shock Center is its commitment to developing the next generation of geroscientists. Through pilot grant programs, mentorship initiatives, trainee internships, educational workshops, and collaborative research opportunities, the Center provides critical support for early-stage investigators pursuing careers in aging research.
Sources: en.wikipedia.org
A defensive reaction of the skin is the formation of a light callus, the skin's own sun protection, which corresponds to a protection factor of about 5. At the same time, the production of brown skin pigments (melanin) in the corresponding cells (melanocytes) is stimulated. A solar control film is usually a film made of polyethylene terephthalate (PET) that is applied to windows to reduce the light and heat from the sun's rays. The film filters UV-A and UV-B radiation. Polyethylene terephthalate goes back to an invention by the two Englishmen John Rex Whinfield (1902-1966) and James Tennant Dickson in 1941.
Already chief scientist, Van de Graaff joined HVEC full-time in 1960. He worked with colleagues to introduce the industrial core transformer. Focused on scientific hypothesis at the frontier of the field, he championed development of the company's most ambitious accelerator. Theoretical models predicted an "island of stability" of superheavy elements—heavy atoms that would resist rapid radioactive decay despite lying beyond uranium on the periodic table. Van de Graaff believed that stable superheavy elements could provide nuclear fuel for long-distance space missions or enable compact nuclear weapons, making superheavy ion synthesis the top priority for accelerator research. The proposed 20-megavolt Transuranium Accelerator (XTU) pushed HVEC accelerators towards this frontier. HVEC invested more than $4.6 million in two XTU prototypes (equivalent to $44.4 million in 2025). Anticipating that laboratories would compete to acquire machines capable of historic discoveries, leadership adopted a "build first and seek customers later" approach. During the XTU's construction in 1967–68, federal support for basic nuclear physics declined sharply. The Vietnam War and Great Society programs drew resources away from fundamental research. Simultaneously, the discovery of sub-atomic quarks put the high-energy frontier of physics research beyond the reach of Van de Graaff accelerators. By the time the XTU passed preliminary tests the following year, the U.S. Atomic Energy Commission had said it would not fund purchases.
== Governance == The South African Government department most related to the country's logistics sector is the Department of Transport (DoT). In 2023, the DoT released a Roadmap for the Freight Logistics System in South Africa. In the document, the government outlined that while it believed that strategic infrastructure such as rail and ports would remain publicly-owned, as it belongs to the people of South Africa, operating of such infrastructure could be opened up to private investment. Doing so, the government believes, will allow for increased efficiencies and competitiveness. The roadmap serves as a guide for state-owned transit company Transnet to achieve this balance, translating policy commitments into actions that are to be taken by the entity. In 2025, one of the themes of the Department of Transport's budget was facilitating the development of the country's air cargo capacity. Part of a R21.7-billion Airports Company South Africa (ACSA) infrastructure development allocation was set aside for increasing air freight handling through its network of airports. South Africa's fuel pipelines are regulated by the National Energy Regulator of South Africa (NERSA).
=== Quality, digestibility and energy density === There are a few key components to consider when evaluating dietary needs. These factors include the quality and digestibility of the protein provided in the diet, as well as the composition of the amino acids included, and finally the energy density provided in the diet. Diets containing proteins that are high in quality, composition, and digestibility require less of that protein to be present. The same can be said in regards to the energy density. In contrast, high-protein diets will provide excess protein content after meeting maintenance demands; this can therefore lead to the protein being utilized in fat and energy storage. This ultimately increases the risk for developing obesity and other health related issues. Higher protein in the diet helps reduce lean body mass loss, but will not lead to an increase in size of muscle unless paired with resistance exercises or anabolic steroids under maintenance conditions.
The battle at Qalabane demoralized the Cape Mounted Yeomanry, which had previously successfully repulsed much larger bodies of enemy troops, but the Basuto hailed the clash as a great victory. Clarke reached Mafeteng, engaging in counter-insurgency operations in its vicinity until the end of the month before returning to the Cape.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.